TEVA
Teva Pharmaceutical Industries Limited
TEVA's fundamentals are weak and it looks expensive: trading at 99x earnings, about four times its usual 26x. Analysts expect strong earnings growth.
TEVA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Weak |
TEVA's cash flow is currently healthy, and its revenue and profitability are stable, but its balance sheet is weak.
TEVA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.18 | -86% |
| Forward | 15x | $43.65 | — |
| Fair | 26x | $11.34 | -74% |
| Expensive | 59x | $25.80 | -41% |
| Current | 99x | $43.65 | — |
Historical ranges are pointers, not guarantees.
TEVA's PE is in its expensive range at 99x. If earnings grow as analysts expect, today's price would be 15x next year's earnings, in its cheap range.
TEVA Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect TEVA's earnings to grow and its profitability to improve, with its revenue holding steady.
TEVA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.82 | +542% |
| Q3 2026 | $0.44 | -27% |
| Q2 2026 | $0.61 | +$0.77 |
| Q1 2026 | $1.34 | +$2.49 |
| Q4 2025 | $1.21 | +$2.66 |
| Q3 2025 | $0.60 | +$1.44 |
| Q2 2025 | -$0.16 | +$0.22 |
| Q1 2025 | -$1.15 | -$0.75 |
| Q4 2024 | -$1.45 | -$0.99 |
TEVA earned $0.44 per share over the past year, down 27% from the year before.
TEVA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.4B | -1.9% |
| Q2 2026 | $4.1B | -0.8% |
| Q1 2026 | $4B | +2.3% |
| Q4 2025 | $1.5B | -65% |
| Q3 2025 | $4.5B | +3.4% |
| Q2 2025 | $4.2B | +0.3% |
| Q1 2025 | $3.9B | +1.9% |
| Q4 2024 | $4.2B | -5.1% |
TEVA's revenue is shrinking: $4.4B last quarter, down 1.9% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | -3.4 points |
| Q2 2026 | -5.6% | -17 points |
| Q1 2026 | 16% | +3 points |
| Q4 2025 | 20% | +21 points |
| Q3 2025 | 20% | +21 points |
| Q2 2025 | 11% | +11 points |
| Q1 2025 | 13% | +19 points |
| Q4 2024 | -0.7% | -17 points |
TEVA's operating margin was 16% last quarter, down 3.4 points from the same quarter a year ago.
TEVA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $121M | -48% |
| Q2 2026 | $307M | +134% |
| Q1 2026 | -$208M | +$24M |
| Q4 2025 | $1B | +128% |
| Q3 2025 | $233M | -57% |
| Q2 2025 | $131M | +2083% |
| Q1 2025 | -$232M | +$16M |
| Q4 2024 | $446M | -58% |
TEVA generated $1.2B in free cash flow over the past year, up 114% from the year before.
TEVA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +18M shares |
| 1 year | +1.6% | +19M shares |
| 3 years | +4.2% | +48M shares |
| 5 years | +6.7% | +74M shares |
| Available history | +8.4% | +92M shares |
TEVA has 1.2B diluted shares, up 1.6% from a year ago.
TEVA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.9x | High |
| Q2 2026 | 6.8x | High |
| Q1 2026 | 4.7x | High |
| Q4 2025 | 4.8x | High |
| Q3 2025 | 5.2x | High |
| Q2 2025 | 8.1x | High |
| Q1 2025 | 10.5x | High |
| Q4 2024 | 21.6x | High |
TEVA's net debt is about 6.9 years of its operating earnings (EBITDA), up from 5.2 years a year ago.
TEVA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.1 | Overbought |
| Stochastic | 93.7 | Overbought |
TEVA's weekly RSI is 70 (overbought) and its Stochastic is 94 (overbought).
TEVA PE vs Healthcare Sector
| Metric | TEVA | Sector median | Relative |
|---|---|---|---|
| PE | 99x | 26x | 284% above |
| PE % | 100 | 29 | 71 pts above |
TEVA is trading at 99x earnings, a 284% premium to the Healthcare sector's median of 26x.
TEVA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $41.1 | 6.1% above |
| 20 week MA | $37.6 | 16% above |
| 50 week MA | $34.4 | 27% above |
| 100 week MA | $26.3 | 66% above |
| 200 week MA | $19.4 | 125% above |
TEVA is in an uptrend: it's above all five of its weekly moving averages, and 125% above its 200-week average.
TEVA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.96 | $9.83 | -1.3% |
| 2021 | $9.83 | $8.46 | -14% |
| 2022 | $8.46 | $9.24 | +9.2% |
| 2023 | $9.24 | $10.4 | +13% |
| 2024 | $10.4 | $22.8 | +118% |
| 2025 | $22.8 | $31.9 | +40% |
| 2026 YTD | $31.9 | $43.7 | +37% |
TEVA has finished higher in four of the last six years. It's up 37% so far in 2026.